Assistant Professor, Oncologic Sciences, USF-Morsani
Oncology
Dr. Alberto A. Chiappori, MD
|
|
Give Review
Doctor Alberto A. Chiappori, MD is an expert in the field of Oncology. Dr. Alberto A. Chiappori has written publications. He has 55 publications published with PubMed. The lastest publication is: 'Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.' He is registered with Medicare and accepts Medicare payments.
Publications
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung Cancer: a single-group, multicentre, phase 2 trial.
- A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung Cancer.
- Temporal trends from 1986 to 2008 in overall survival of small cell lung Cancer patients.
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung Cancer (AF-002J...
- Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patien...
- Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations.
- Current clinical application of genomic and proteomic profiling in non-small-cell lung Cancer.
- Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung Cancer.
- Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell-based Vaccine for Refractory Lung Adenocarcinoma.
- Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung Cancer.
- Therapeutic regulation of myeloid-derived suppressor cells and immune response to Cancer vaccine in patients with extensive stage small cell lung Cancer.
- Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings.
- Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung Cancer.
- Combination of HDAC and topoisomerase inhibitors in small cell lung Cancer.
- Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.
- Lung Cancer mutations and use of targeted agents in hispanics.
- A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-sta...
- Cardiac toxicity: old and new issues in anti-Cancer drugs.
- Prevalence of post-partum thyroiditis in Liguria (Italy): an observational study.
- Prevalence and prognostic significance of neuroendocrine Cells in esophageal adenocarcinoma.
- Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenoCarcinomas.
- [Adhesive peritonitis caused by a foreign body. A case report].
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
- Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism: comparison between different methods.
- Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage ...
- Lung Cancer after 70: is it a different disease?
- A pilot study of preoperative gefitinib for early-stage lung Cancer to assess intratumor drug concentration and pathways mediating primary resistance.
- Molecular origins of lung Cancer: prospects for personalized prevention and therapy.
- INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung Cancer: observed association between immune response and enhanced chemotherapy effect.
- Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung Cancer.
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid Tumors.
- Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung Cancer.
- Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung Cancer.
- A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung Cancer.
- Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung Cancer.
- Increased cyclin D3 expression significantly correlates with p27 nuclear positivity in gastrointestinal stromal Tumors.
- Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small Cell lu...
- Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung Cancer (NSCLC) who are 70 years of age or older.
- Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
- Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung Cancer.
- Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung Cancer.
- Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid Tumors: a clinical and transla...
- A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung Cancer.
- A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid Tumors.
- Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small Cell and neuroendo...
- Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
- Combination of p53 Cancer vaccine with chemotherapy in patients with extensive stage small cell lung Cancer.
- Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
- Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung Cancer.
- New agents in the treatment of small-cell lung Cancer: focus on gemcitabine.
- Gefitinib (ZD1839) in previously treated advanced non-small-cell lung Cancer: experience from a single institution.
- Treatment of relapsed small-cell lung Cancer--a focus on the evolving role of topotecan.
- A Phase I study of indoximod in patients with advanced malignancies.
- Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis.
Schools
Cayetano Heredia University Of PeruMd
Southern Ill University
Universidad Cayetano Heredia
Southern Illinois University School Of Medicine
Vanderbilt University School Of MedicineHematologyOncology
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Education
-
Vanderbilt University -
Southern Illinois University -
Cayetano Heredia University
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1952331654 | |
| NPPES Provider LastName | CHIAPPORI | |
| NPPES Provider FirstName | ALBERTO | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 370.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 75.0 | |
| Percent Opioid Claims | 20.27 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952331654 |
| Last Name Of The Provider | CHIAPPORI |
| First Name Of The Provider | ALBERTO |
| View All |
Similar Doctors
|
Dr. Khaldoun Almhanna, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Bryan McIver, MD |
|
Dr. Amit Mahipal, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ramesh Shah, MD
This Doctor is OpenDoctor Recommended.
|